<DOC>
	<DOCNO>NCT01789619</DOCNO>
	<brief_summary>To evaluate clinical efficacy extend release formulation tacrolimus ( Advagraf® ) patient severe atopic dermatitis , treat adequately cyclosporine A side effect and/or non-responsiveness .</brief_summary>
	<brief_title>Extended Release Tacrolimus ( Advagraf® ) Severe Adult Atopic Dermatitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Adult patient severe atopic dermatitis , uncontrolled topical treatment ( indication oral immunosuppressive drug ) , unresponsive Cyclosporin A , treatment discontinue side effect . Concomitant use oral immunosuppressive drug and/or UV light therapy Preexisting abnormality liver function , kidney function haematological abnormality History malignancy within last 5 year Uncontrolled hypertension Pregnancy lactation ; wish pregnancy treatment period Infections require continued therapy Known positivity HIV Evidence drug and/or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>